Endothelial cells, which are nonhemopoietic cells, express and/or produce most of the known hemopoietic receptors and cytokines. The biological role of these factors, and their respective receptors, on endothelial cells is still unknown. In this study, the authors assessed the effect of different hemopoietic growth factors, ie, interleukin-3 (IL-3), erythropoietin (EPO), macrophage-colony stimulating factor (M-CSF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), singly or in conjunction with others, on proliferation and chemotaxis of human umbilical vein endothelial cells (HUVECs). They found growth stimulatory activity with IL-3, EPO, and GM-CSF and potent synergism between EPO and IL-3, less with IL-3 and GM-CSF, and none with EPO and either GM-CSF or G-CSF. All the singly tested hemopoietic growth factors stimulated the migration of HUVECs, but in conjunction with other factors, they did not show any additive or synergistic effect.
Kahaleh MB: The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol10:51-56, 1992.
3.
Hirschberg H. , Bergh OJ, Thorsby E.: Antigen presenting properties of human vascular endothelial cells. J Exp Med152:249S-255S, 1980.
4.
Favaloro EJ, Moraitis N., Bradstock K., et al: Co-expression of hemopoietic antigens on vascular endothelial cells: A detailed phenotypic analysis. Br J Hematol74:385-394, 1990.
5.
Fina L., Molgaard HV, Robertson D., et al: Expression of the CD34 gene in vascular endothelial cells. Blood75:2417-2426, 1990.
6.
Peault BM, Thiery JP, Le Douarin NM: Surface marker for hemopoietic and endothelial cell lineages in quail that is defined by a monoclonal antibody. Proc Natl Acad Sci USA80:2976-2980, 1983.
7.
Aye MT, Hashemi S., Leclair B., et al: Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF). Exp Hematol20:523-527, 1993.
8.
Boraschi D., Rambaldi A., Sica A., et al: Endothelial cells express the interleukin-1 receptor type I . Blood78:1262-1267, 1991 .
9.
Hicks C., Cooley MA, Penny R.: Investigation of interleukin 2 receptors on human endothelial cells . Growth Factors5:201-208, 1991.
10.
Bagby GC Jr, Dinarello CA, Wallace P., et al: Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest78:1316-1323, 1986.
11.
Fibbe WE, Daha MR, Hiemstra PS, et al: Interleukin 1 and Poly(rl):Poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells . Exp Hematol17:229-234, 1989.
12.
Korpelainen EI, Gamble JR, Smith WB, et al: The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor α and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci USA90:11137-11141, 1993 .
13.
Mantovani A. , Dejana E.: Cytokines as communication signals between leukocytes and endothelial cells . Immunol Today10:370-375, 1989.
14.
Podor TJ, Jirik FR, Loskutoff DJ, et al: Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann NY Acad Sci557:374-377, 1989.
15.
Bussolino F. , Wang JM, Defilippi P., et al: Granulocyte-and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate . Nature337:471-473, 1989.
16.
Brizzi MF, Garbarino G., Rossi PR, et al: Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells. J Clin Invest91:2887-2892, 1993.
17.
Anagnostou A., Lee ES, Kessimian N., et al: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA87:5978-5982, 1990 .
18.
Van Hinsbergh VW, Mommaas-Kienhuis AM, Weinstein R., et al: Propagation and morphologic phenotypes of human umbilical cord artery endothelial cells . Eur J Cell Biol42:101-110, 1989.
19.
Shultz PJ, DiCorleto PE, Silver BJ, et al: Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol255:F674-684, 1988 .
20.
Connolly DT , Stoddard BL, Harakas NK, et al: Human fibroblast-derived growth factor is a mitogen and chemoattractant for endothelial cells. Biochem Biophys Res Commun144:705-712, 1987.
21.
Penn PE, Jiang DZ, Fei RG, et al: Dissecting the hematopoietic microenvironment. IX. Further characterization of murine bone marrow stromal cells. Blood81:1205-1213, 1993.
22.
Keating A., Singer JW, Killen PD, et al: Donor origin of the in vitro hematopoietic microenvironment after marrow transplantation in man. Nature298:280-283, 1982.
23.
Yanai N., Satoh T., Obinata M.: Endothelial cells create a hematopoietic inductive microenvironment preferential to erythropoiesis in the mouse spleen. Cell Struct Funct16:87-93, 1991.
24.
Mantovani A. , Bussolino F., Dejana E.: Cytokine regulation of endothelial cell function . FASEB J6:2591-2599, 1992 .
25.
Anagnostou A., Liu Z., Steiner M., et al: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA91:3974-3978, 1994.
26.
Yong K., Cohen H., Khwaja A., et al: Lack of effect of granulocyte-macrophage and granulocyte colony-stimulating factors on cultured human endothelial cells. Blood77:1675-1680, 1991.
27.
Colotta F., Bussolino F., Polentarutti N., et al: Differential expression of the common β and specific α chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells. Exp Cell Res206:311-317, 1993.
28.
Metcalf D.: Implications of the polyfunctionality of hemopoietic regulators. Stem Cells12:259-275, 1994.
29.
Raine Aeg: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet1:97-100, 1988.
Heidenreich S., Rahn KH, Zidek W.: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int39:259-265, 1991.
33.
Singbartl G. : Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Invest72(suppl 6):S36-S43, 1994.
34.
Ballmer-Weber BK, Dummer R., Kung E., et al: Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer71:78-82, 1995.
35.
Olthof CG, Baars JW, Wagstaff J., et al: Determination of capillary leakage due to recombinant interleukin-2 by means of noninvasive conductivity measurements. Eur J Applied Phys Occup Phys67:168-173, 1993.
36.
Ganser A., Lindemann A., Seipelt G., et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood76:666-676, 1990.
37.
de Vries EG , van Gameren MM, Willemse PH: Recombinant human interleukin 3 in clinical oncology. Stem Cells11:72-80, 1993.
38.
D'Hondt V., Guillaume T., Humblet Y., et al: Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: A pilot study. Bone Marrow Transplantation13:261-264, 1994.
